Welcome to our dedicated page for Bausch Health Companies SEC filings (Ticker: BHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bausch Health Companies Inc. filings document regulatory disclosures for a global diversified pharmaceutical company incorporated in British Columbia. The record includes Form 8-K reports for quarterly and annual operating results, Regulation FD updates, clinical-program disclosures, material agreements, debt exchanges and credit-agreement refinancing involving Bausch Health and its subsidiaries, including Bausch + Lomb.
Proxy materials describe annual meeting matters, director elections, auditor approval, executive compensation votes and governance procedures. Other current reports address compensatory arrangements, including performance share unit settlement terms, and capital-structure disclosures tied to senior secured notes, guarantees, collateral arrangements and refinancing transactions.
WECHSLER AMY B reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Amy B. Wechsler received an award of 45,871 restricted share units (RSUs) of common shares. The RSUs have a grant date value of $250,000, will vest immediately before the company’s next Annual Meeting of Shareholders, and will be settled in common shares. Following this grant, Wechsler directly holds 313,585 common shares.
ROBERTS EIRY reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Eiry Roberts received a compensation-related equity grant. On May 22, 2026, she was awarded 45,871 restricted share units (RSUs), which will be settled in common shares at no purchase price. The RSUs have a grant date value of $250,000, vest on the date immediately preceding the company’s next annual meeting of shareholders, and are intended for non-employee directors. Following this grant, Roberts holds 45,871 common shares directly, showing this is an initial or refreshed equity position rather than an open-market purchase or sale.
POWER ROBERT N reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. reported that director Robert N. Power received an equity grant in the form of restricted share units. He was awarded 45,871 RSUs with a grant date value of $250,000, which will vest immediately before the company’s next Annual Meeting of Shareholders and be settled in common shares. Following this grant, he directly holds 300,594 common shares.
Paulson John reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director John Paulson reported an equity compensation grant rather than an open-market trade. He received an award of 45,871 restricted share units with a grant date value of $250,000, which vest on the date immediately preceding the company’s next annual meeting and will be settled in common shares.
Following this award, Paulson directly holds 417,565 common shares. Investment funds managed by Paulson Capital Inc. directly hold 73,255,869 common shares; Paulson may be deemed an indirect beneficial owner of those fund holdings but disclaims beneficial ownership except to the extent of his pecuniary interest.
LEUNG SANDRA reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Sandra Leung received an equity award as part of her board compensation. She was granted 45,871 restricted share units with a grant date value of $250,000, which will vest on the date immediately before the company’s next Annual Meeting of Shareholders and be settled in common shares. Following this award, she beneficially owns 90,225 common shares directly.
Lee Frank D. reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Frank D. Lee received an equity grant in the form of restricted share units. On the grant date, he was awarded 45,871 RSUs with a grant date value of $250,000, at a per-share price of $0.00 as a non-cash compensation award.
The RSUs were granted to non-employee directors on the third business day following their election at the Annual Meeting of Shareholders. They vest on the date immediately preceding the next Annual Meeting of Shareholders and will be settled in common shares. Following this grant, Lee directly owns 95,210 common shares.
KAVANAGH SARAH B reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Sarah B. Kavanagh received an equity grant tied to her board service. She was awarded 45,871 common shares in the form of restricted share units (RSUs) with a grant date value of $250,000, at no cash cost to her.
The RSUs vest on the date immediately preceding the company’s next Annual Meeting of Shareholders and will be settled in common shares. Following this award, Kavanagh directly holds 282,230 common shares, reflecting routine, compensation-related stock-based pay for a non-employee director rather than an open-market purchase or sale.
GOETTLER MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Michael Goettler received an equity compensation grant in the form of 45,871 restricted share units (RSUs) with a stated grant date value of $250,000. These RSUs vest immediately before the company’s next Annual Meeting of Shareholders and will be settled in common shares, increasing his direct holdings to 76,020 shares.
Garcia Christian A reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Christian A. Garcia received an award of 45,871 common shares on May 22, 2026, reported as restricted share units granted to non-employee directors. The RSUs have a grant-date value of $250,000 and vest immediately before the company’s next Annual Meeting of Shareholders.
After this equity award, Garcia directly holds 135,578 common shares. The RSUs will be settled in Bausch Health common shares when they vest, increasing his share ownership if he continues to serve through the vesting date.
Bausch Health Companies Inc. director Frank D. Lee reported an open-market sale of common shares. On May 19, 2026, he sold 24,456 common shares at an average price of $5.43 per share. Following this transaction, he directly holds 49,339 common shares.
According to the footnote, the shares were sold in the open market under a Rule 10b5-1 trading plan to fund estimated tax obligations from a previously vested equity award granted to the company’s non-employee directors. The filing shows no derivative positions remaining in this report.